Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BITR2101
- Development stage
- Phase 1
- Lead developer
- Boston Immune Technologies and Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BITR2101 is a monoclonal antibody developed by Boston Immune Technologies and Therapeutics (BITT) that targets tumor necrosis factor receptor 2 (TNFR2), a member of the TNF receptor superfamily. TNFR2 is highly expressed on certain tumor cells and immunosuppressive cells in the tumor microenvironment, such as regulatory T cells (Tregs) and myeloid-derived suppressor cells. By antagonizing TNFR2, BITR2101 aims to disrupt immune suppression within tumors and enhance anti-tumor immune responses. The drug is being investigated primarily for the treatment of cancers including non-Hodgkin lymphoma, cutaneous T-cell lymphoma (CTCL), and peripheral T-cell lymphoma. Clinical trials are ongoing to evaluate its efficacy both as a single agent and in combination with other immunotherapies like tislelizumab[3][4][5][6][7].
- Other names
- Anti-TNFR2Anti-TNFR-2Anti-TNFR 2
02
Targets
TNFR2 (Tumor necrosis factor receptor superfamily member 1B)
Beyond the preview
Go deeper on BITR2101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BITR2101.